Neurofibromatosis Type 1 research hub
3 indexed studies · 1 currently recruiting
- active not recruiting
PASS of Paediatric Patients Initiating Selumetinib
This study looks at the safety of selumetinib for children aged 3-17 with Neurofibromatosis Type 1 (NF1) and certain nerve tumours (plexiform neurofibromas). It helps doctors understand the medicine's long-term effects in real-world use.
Austria · France · Germany - recruitingPHASE4
Pediatric Long-Term Follow-up and Rollover Study
This study looks at the long-term well-being of children and young people who have been treated with specific medications (dabrafenib and/or trametinib) for certain brain cancers in previous clinical trials. It aims to understand the lasting effects of these treatments.
United States · Argentina · Australia - authorisedTherapeutic exploratory (Phase II)
Trametinib in neurofibromatosis type 1 related symptomatic plexiform neurofibromas
This study is looking into a new tablet called Mekinist for people with Neurofibromatosis Type 1 (NF1) and painful nerve tumours. It aims to see if Mekinist can shrink these tumours and improve quality of life.
Netherlands